FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. Released May 22, 2017

Focus on Cancer

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.

About

Focus on Cancer